<DOC>
	<DOCNO>NCT00319033</DOCNO>
	<brief_summary>This study asses long term safety efficacy oral bosentan patient suffer Interstitial Lung Disease .</brief_summary>
	<brief_title>Open-label Study With Bosentan Interstitial Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>To complete 12month treatment period AC052330/BUILD 2 . Women pregnant Women childbearing potential must negative pretreatment pregnancy test use reliable method contraception Signed informed consent prior initiation studymandated procedure Any major violation protocol AC052330 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>interstitial lung disease</keyword>
	<keyword>scleroderma</keyword>
	<keyword>bosentan</keyword>
</DOC>